These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18447601)

  • 1. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
    Prandoni P; Tormene D; Perlati M; Brandolin B; Spiezia L
    Expert Opin Investig Drugs; 2008 May; 17(5):773-7. PubMed ID: 18447601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idraparinux and idrabiotaparinux.
    Harenberg J
    Expert Rev Clin Pharmacol; 2010 Jan; 3(1):9-16. PubMed ID: 22111528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended prophylaxis of venous thromboembolism with idraparinux.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
    ; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
    Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
    Harenberg J
    Thromb Haemost; 2009 Nov; 102(5):811-5. PubMed ID: 19888513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.
    Song Y; Li X; Pavithra S; Li D
    PLoS One; 2013; 8(11):e78972. PubMed ID: 24278113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idraparinux versus standard therapy for venous thromboembolic disease.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1094-104. PubMed ID: 17855670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
    Equinox Investigators
    J Thromb Haemost; 2011 Jan; 9(1):92-9. PubMed ID: 20946157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.
    Veyrat-Follet C; Vivier N; Trellu M; Dubruc C; Sanderink GJ
    J Thromb Haemost; 2009 Apr; 7(4):559-65. PubMed ID: 19187079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idraparinux sodium. Sanofi-Aventis.
    Ma Q; Fareed J
    IDrugs; 2004 Nov; 7(11):1028-34. PubMed ID: 15551178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
    Trellu M; Fau JB; Cortez P; Cheng S; Paty I; Boëlle E; Donat F; Sanderink GJ
    Br J Clin Pharmacol; 2013 May; 75(5):1255-64. PubMed ID: 23078631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.
    van Doormaal FF; Cohen AT; Davidson BL; Decousus H; Gallus AS; Gent M; Piovella F; Prins MH; Raskob GE; Büller HR
    Thromb Haemost; 2010 Jul; 104(1):86-91. PubMed ID: 20508907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
    Drouet L
    Bull Acad Natl Med; 2003; 187(1):85-96; discussion 96-7. PubMed ID: 14556456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
    Paty I; Trellu M; Destors JM; Cortez P; Boëlle E; Sanderink G
    J Thromb Haemost; 2010 Apr; 8(4):722-9. PubMed ID: 20088937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idraparinux sodium: SANORG 34006, SR 34006.
    Drugs R D; 2004; 5(3):164-5. PubMed ID: 15139779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs].
    Falciani M; Imberti D; Prisco D
    Recenti Prog Med; 2005 Apr; 96(4):196-204. PubMed ID: 15932039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.
    Savi P; Herault JP; Duchaussoy P; Millet L; Schaeffer P; Petitou M; Bono F; Herbert JM
    J Thromb Haemost; 2008 Oct; 6(10):1697-706. PubMed ID: 18647228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.
    Harenberg J; Jörg I; Vukojevic Y; Mikus G; Weiss C
    Eur J Clin Pharmacol; 2008 Jun; 64(6):555-63. PubMed ID: 18283446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.